Assessment of gastric carcinoma risk associated with Helicobacter pylori may vary depending on the antigen used : Caga specific enzyme-linked immunoadsorbent assay (ELISA) versus commercially available H. pylori ELISAs
✍ Scribed by Shin Maeda; Haruhiko Yoshida; Keiji Ogura; Yutaka Yamaji; Tsuneo Ikenoue; Toru Mitsushima; Hitoshi Tagawa; Ryuji Kawaguchi; Kiyoshi Mori; Ken-ichi Mafune; Takao Kawabe; Yasushi Shiratori; Masao Omata
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 75 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Previous epidemiologic studies produced inconsistent results when examining the relation between Helicobacter pylori infection and the risk of gastric carcinoma by measuring various anti-H. pylori antibodies. This study investigated the increased risk of cancer by examining different antibodies, including the specific anti-CagA antibody and antibodies from two commercially available kits.
METHODS. An ELISA for the detection of serum anti-CagA was established using a recombinant CagA protein that the authors previously reported. Serum anti-CagA titer was determined for 80 patients with gastric carcinoma and 80 gender-and age-matched controls. Two anti-H. pylori antibodies from the commercially available kits HEL-p (Amrad, Kew Vic, Australia) and HM-CAP (Enteric Product Inc., Westbury, NY) were also evaluated.
RESULTS.
Anti-CagA seropositivity differed significantly between gastric carcinoma patients and controls (92.5% vs. 55.0%; P ϭ 0.0001), showing an odds ratio of 10.4 (95% confidence interval [CI]: 4.23-29.74). The difference was less prominent for the seropositivity of HEL-p (77.5% vs. 58.8%; P ϭ 0.0139; odds ratio: 2.38; 95% CI: 1.20 -4.82) and insignificant for that of HM-CAP (65.0% vs. 57.5%; P ϭ 0.4325; odds ratio: 1.30; 95% CI: 0.68 -2.49).
CONCLUSIONS.
The current study revealed that the antibody assay system used could be one important factor in the assessment of gastric carcinoma risk for patients with H. pylori.